Erik Allman, Ph.D.
Dynamic Omics Group, AstraZeneca
Dr. Erik Allman is a Scientist I in the Dynamic Omics group at AstraZeneca. Erik’s experience in metabolomics is wide-ranging, having utilized mass spectrometry-based methods to study various biological systems and processes, from the identification of antimalarial modes of action to the study of host-metabolite-microbiota interactions in NAFLD. As part of AstraZeneca, Erik and the Dynamic Omics group employ a variety of mass spectrometry methods (LC-MS, GC-MS, CE-MS, and IM-MS) and multi-omics (metabolomic and proteomic) analysis to facilitate their studies of molecular pathways and understand how modulation of these can be leveraged to treat disease and positively impact human health.
Author information: Erik Allman, Matthew Glover, Cristina Di Poto, Lisa Cazares, and Sonja Hess
Dynamic Omics, Antibody Discovery & Protein Engineering, R&D, AstraZeneca, Gaithersburg, US